BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Cord Blood » Page 53

Cord Blood

Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.

Cord Blood Industry News Round-Up | July 2015

July 8, 2015 By Cade Hildreth (CEO) Leave a Comment

CORD BLOOD INDUSTRY NEWS ROUND-UP | JULY 2015

The cord blood banking industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.

While it may be possible to stay informed about cord blood industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant cord blood industry events for July 2015.

[Read more…]

Filed Under: Cord Blood Tagged With: Americord Registry, artificial blood transfusion, cord blood, Smart Cells International, UCB, umbilical cord blood

5 Types of Cord Blood Market Participants Impacted by AMAG Pharma’s Acquisition of Cord Blood Registry (CBR®)

June 30, 2015 By Cade Hildreth (CEO) Leave a Comment

Cord Blood Registry Acquired by AMAG Pharmaceuticals

On June 29, 2015, AMAG Pharmaceuticals released news that reverberated throughout the cord blood banking industry worldwide, announcing that it had entered into a definitive agreement to acquire Cord Blood Registry (CBR®) for $700 million. The acquisition is expected to close during the third-quarter of 2015, based on regulatory approvals and execution of agreed upon terms and conditions.

Direct Participants in the Cord Blood Deal

Founded in 1992 and headquartered in San Bruno, California, Cord Blood Registry® is the largest cord blood bank in the United States and the world.  CBR® currently stores over 500,000 preserved cord blood and cord tissue units, which is substantially more than its nearest competitor, ViaCord, which has approximately 350,000 units stored.   [Read more…]

Filed Under: Cord Blood, HSCs, Stem Cells Tagged With: acquisition, AMAG Pharmaceuticals, cord blood, Cord Blood Registry

Stem Cell Biobanking Market: 9 Market Segments to Know

June 24, 2015 By Cade Hildreth (CEO) Leave a Comment

Stem Cell Biobanking Market

Introduction to the Stem Cell Biobanking Market

“Stem cell biobanking” is the cryogenic storage of stem cells, or biological samples containing stem cells, for use at a later point in time. Therefore, the “stem cell biobanking market” is defined as the total annual revenue derived from the storage of:

  1. Stem cell lines and their derivatives
  2. All biological samples that were collected specifically because they contain stem cell populations (e.g. cord blood, adipose tissue, and more)

For company executives and investors that are competing within the stem cell biobanking marketplace, it is important to know the nine market segments that compose the stem cell biobanking market at large.
[Read more…]

Filed Under: Cord Blood, Stem Cells Tagged With: market research, market segments, stem cell biobanking, stem cell biobanking market, stem cell market, stem cells

Cord Blood is 2nd Most Common Source of Stem Cells for Cell Therapy

June 22, 2015 By Cade Hildreth (CEO) Leave a Comment

Identifying Hemapoietic Stem Cell Transplant Trends

For those competing within the cord blood marketplace, it is valuable to know that umbilical cord blood is the second most common source of stem cells for cellular therapy.

Because it is a rich source of highly primitive hematopoietic stem cells, umbilical cord blood has enormous regenerative potential for stem cell-based-therapy, both for the treatment of hematological and non-hematological disorders. Indeed, with the recent expansion in stem cell research and an increase in public interest in stem cell-based therapies, researchers are now exploring the potential of umbilical cord blood stem cells for non-hematological disorders.

This is evidenced by the increasing number of clinical trials that are utilizing umbilical cord blood stem cell-based therapies to treat a range of diseases.

However, with these advances come new standards that must be established, including:

  • Standardization of criteria for the selection of umbilical cord blood (UCB) units for stem cell-based therapies
  • Outcome measures
  • Long-term follow-up

Additionally, it is controversial within medical communities to use umbilical cord blood stem cells for non-hematological disorders, a perspective which is gradually starting to change. Clearly, therapeutic use of cord blood stem cells will play an important role in the future of regenerative medicine, but its applications and limitations of use have yet to be defined.

Filed Under: Cord Blood, HSCs Tagged With: bone marrow, cord blood, HSCT

Cord Blood Industry News Round-Up | June 2015

June 21, 2015 By Cade Hildreth (CEO) Leave a Comment

Cord Blood Industry News Round-Up | JUNE 2015

The cord blood banking industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.

While it may be possible to stay informed about cord blood industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant cord blood industry events for June 2015.

[Read more…]

Filed Under: Cord Blood, HSCs, MSCs Tagged With: Americord Registry, cord blood, Cord Blood Registry, current events, delayed cord clamping, industry news, SynGen, UCB, UCBT, umbilical cord blood transplantation

  • « Previous Page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • …
  • 58
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97

Featured Posts

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

Feature | Exosome Companies | Exosome Companies | Tiny Exosomes, Enormous Potential

List of Exosome Companies: Tiny Packages, Enormous Potential

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.